TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52)

3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control arm

TSC-101 was well-tolerated with no dose-limiting toxicities observed

Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc. on Monday, December 8, at 8:00 a.m. ET

WALTHAM, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced updated results from the ongoing ALLOHA Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The data is being featured in a poster presentation at the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition.

“These updated data from our Phase 1 study continue to highlight a positive safety and efficacy profile of TSC-101 in patients with heme malignancies undergoing allogeneic HCT. All three patients who reached two years of follow-up have no detectable disease as they have remained relapse-free and in complete donor chimerism,” said Chrystal U. Louis, M.D., Chief Medical Officer. “Additionally, there have been no dose-limiting toxicities and patients who received TSC-101 continue to show improved relapse-free and overall survival compared to control-arm patients. We remain focused on enrolling the remaining patients necessary to support our fixed-dosing regimen and look forward to initiating our pivotal study in the second quarter of 2026.”

“Bone marrow transplantation is currently the only curative treatment for patients with AML and MDS. Unfortunately, roughly 40% of these patients relapse within two years of transplant, at which point their prognosis is very poor and the majority will die due to their disease,” added Gavin MacBeath, Ph.D., Chief Executive Officer. “We are excited to see durable responses to TSC-101 and continued positive data, in the hopes of addressing this unmet need. We look forward to expanding our heme program in 2026 with product candidates designed to double the addressable patient population.”